Editas Medicine Announces Stock and Warrant Offering; Shares Drop Sharply in Premarket
Editas Medicine disclosed an underwritten public offering of common stock and accompanying warrants, triggering a 14.1% decline in premarket trading. The financing announcement comes as the company reports encouraging preclinical results for its lead in vivo candidate EDIT-401 and progresses regulatory interactions ahead of a planned first-in-human…